Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

terleukin-10 serum levels for Hodgkin's
disease. Ann. Hematol. 79: 110.
116 Sarris, A. H., K. O. Kliche, P. Pethambaram,
A. Preti, S. Tucker, C. Jackow,
O. Messina,W. Pugh, F. B. Hagemeister,
P. McLaughlin, M. A. Rodriguez,
J. Romaguera, H. Fritsche,T. Witzig,
M. Duvic, M. Andreeff and F. Cabanillas.
1999. Interleukin-10 levels are often
elevated in serum of adults with
Hodgkin's disease and are associated
with inferior failure-free survival. Ann.
Oncol 10: 433.
117 Axdorph, U., J. Sjoberg, G. Grimfors,
O. Landgren, A. Porwit-Mac-
Donald and M. Bjorkholm. 2000. Biological
markers may add to prediction
of outcome achieved by the International
Prognostic Score in Hodgkin's
disease. Ann. Oncol. 11: 1405.
118 Nemunaitis, J., T. Fong, P. Shabe,
D. Martineau and D. Ando. 2001.
Comparison of serum interleukin-10
(IL-10) levels between normal volunteers
and patients with advanced melanoma.
Cancer Invest. 19: 239.
119 Berghella, A. M., P. Pellegrini,
T. Del Beato, D. Adorno and
C. U. Casciani. 1997. IL-10 and sIL-2R
serum levels as possible peripheral
blood prognostic markers in the passage
from adenoma to colorectal cancer.
Cancer Biother. Radiopharm. 12: 265.
120 Chau, G. Y., C. W. Wu,W. Y. Lui,
T. J. Chang, H. L. Kao, L. H. Wu,
K. L. King, C. C. Loong, C. Y. Hsia
and C. W. Chi. 2000. Serum interleukin-10
but not interleukin-6 is related to
clinical outcome in patients with resectable
hepatocellular carcinoma. Ann.
Surg. 231: 552.
121 De Vita, F., M. Orditura, G. Galizia,
C. Romano, E. Lieto, P. Iodice, C. Tuccillo
and G. Catalano. 2000. Serum
interleukin-10 is an independent prognostic
factor in advanced solid tumors.
Oncol. Rep. 7: 357.
122 Silvestre, J. S., Z. Mallat, M. Duriez,
R. Tamarat, M. F. Bureau, D. Scherman,
N. Duverger, D. Branellec,
A. Tedgui and B. I. Levy. 2000. Antiangiogenic
effect of interleukin-10 in
ischemia-induced angiogenesis in mice
hindlimb. Circ. Res. 87: 448.
References
123 Hatanaka, H.,Y. Abe, M. Naruke,
T. Tokunaga,Y. Oshika, T. Kawakami,
H. Osada, J. Nagata, J. Kamochi,
T. Tsuchida, H. Kijima, H. Yamazaki,
H. Inoue,Y. Ueyama and M. Nakamura.
2001. Significant correlation between
interleukin 10 expression and
vascularization through angiopoietin/
TIE2 networks in non-small cell lung
cancer. Clin. Cancer Res. 7: 1287.
124 de Waal Malefyt, R., J. Abrams,
B. Bennett, C. G. Figdor and J. E. de
Vries. 1991. Interleukin 10 (IL-10) inhibits
cytokine synthesis by human
monocytes: an autoregulatory role of
IL-10 produced by monocytes. J. Exp.
Med. 174: 1209.
125 Fiorentino, D. F., A. Zlotnik,
T. R. Mosmann, M. Howard and
A. O'Garra. 1991. IL-10 inhibits cytokine
production by activated macrophages.
J. Immunol. 147: 3815.
126 Berg, D. J., J. Zhang, D. M. Lauricella
and S. A. Moore. 2001. IL-10 is a
central regulator of cyclooxygenase-2
expression and prostaglandin production.
J. Immunol. 166: 2674.
127 Gazzinelli, R. T., I. P. Oswald,
S. Hieny, S. L. James and A. Sher.
1992. The microbicidal activity of interferon-g-treated
macrophages against
Trypanosoma cruzi involves an l-arginine-dependent,
nitrogen oxidemediated
mechanism inhibitable by interleukin-10
and transforming growth
factor-b. Eur. J. Immunol. 22: 2501.
128 Oswald, I. P., R. T. Gazzinelli,
A. Sher and S. L. James. 1992. IL-10 synergizes
with IL-4 and transforming
growth factor-b to inhibit macrophage
cytotoxic activity. J. Immunol. 148: 3578.
129 de Waal Malefyt, R., J. Haanen,
H. Spits, M. G. Roncarolo,V. A. te,
C. Figdor, K. Johnson, R. Kastelein,
H. Yssel and J. E. de Vries. 1991. Interleukin
10 (IL-10) and viral IL-10
strongly reduce antigen-specific human
T cell proliferation by diminishing the
antigen-presenting capacity of monocytes
via downregulation of class II major
histocompatibility complex expression.
J. Exp. Med. 174: 915.
130 Koppelman, B., J. J. Neefjes, J. E. de
Vries and R. de Waal Malefyt. 1997.
143